Regulation - Sandoz, Regulation


Current filters:


Popular Filters

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars


Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler


Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

Apricus ED drug gains national phase approval in Germany


Germany's Federal Institute for Drugs and Medical Devices has granted national phase approval for USA-based…

Apricus BioscienceEuropeMen's HealthPharmaceuticalRegulationSandozVitaros

Proposal for a sole supply arrangement for fentanyl patches in New Zealand


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

Pharma giants included in China's investigation into pricing of foreign imports


China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

FDA warns Novartis on Austrian generic manufacturing plant cGMP failures


The US Food and Drug Administration has written to Joseph Jimenez, chief executive of Swiss drug major…

Ebewe PharmaGenericsNovartisProductionRegulationSandoz

Sandoz to emphasize need for consistent regulatory standards across all biologics at FDA hearings


Germany-based Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX) announced that Mark McCamish,…

BiotechnologyGeneralNorth AmericaNovartisRegulationResearchSandoz

Sandoz challenges United Thera’s Remodulin patents


US drugmaker United Therapeutics (Nasdaq: UTHR) says that it has received a Paragraph IV Certification…

GenericsNorth AmericaNovartisPatentsPharmaceuticalRegulationRemodulinRespiratory and PulmonarySandozUnited Therapeutics

Back to top